Solid lipid nanoparticles (Slns): An advanced drug delivery system targeting brain through bbb

Mantosh Kumar Satapathy, Ting Lin Yen, Jing Shiun Jan, Ruei Dun Tang, Jia Yi Wang, Rajeev Taliyan, Chih Hao Yang

研究成果: 雜誌貢獻回顧型文獻同行評審

62 引文 斯高帕斯(Scopus)


The blood–brain barrier (BBB) plays a vital role in the protection and maintenance of homeostasis in the brain. In this way, it is an interesting target as an interface for various types of drug delivery, specifically in the context of the treatment of several neuropathological conditions where the therapeutic agents cannot cross the BBB. Drug toxicity and on-target specificity are among some of the limitations associated with current neurotherapeutics. In recent years, advances in nanodrug delivery have enabled the carrier system containing the active therapeutic drug to target the signaling pathways and pathophysiology that are closely linked to central nervous system (CNS) disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), multiple sclerosis (MS), brain tumor, epilepsy, ischemic stroke, and neurodegeneration. At present, among the nano formulations, solid lipid nanoparticles (SLNs) have emerged as a putative drug carrier system that can deliver the active therapeutics (drug-loaded SLNs) across the BBB at the target site of the brain, offering a novel approach with controlled drug delivery, longer circulation time, target specificity, and higher efficacy, and more importantly, reducing toxicity in a biomimetic way. This paper highlights the synthesis and application of SLNs as a novel nontoxic formulation strategy to carry CNS drugs across the BBB to improve the use of therapeutics agents in treating major neurological disorders in future clinics.
出版狀態已發佈 - 8月 2021

ASJC Scopus subject areas

  • 藥學科學


深入研究「Solid lipid nanoparticles (Slns): An advanced drug delivery system targeting brain through bbb」主題。共同形成了獨特的指紋。